A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer

LESSONS LEARNED: This phase I study evaluated the maximum tolerated dose, dose-limiting toxicities, safety, pharmacokinetics, and efficacy of icotinib with a starting dose of 250 mg in pretreated, advanced non-small cell lung cancer patients. We observed a maximum tolerated dose of 500 mg with a fav...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jian, Wu, Lihua, Wu, Guolan, Hu, Xingjiang, Zhou, Huili, Chen, Junchun, Zhu, Meixiang, Xu, Wei, Tan, Fenlai, Ding, Lieming, Wang, Yinxiang, Shentu, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189627/
https://www.ncbi.nlm.nih.gov/pubmed/27789778
http://dx.doi.org/10.1634/theoncologist.2016-0256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189627/
https://www.ncbi.nlm.nih.gov/pubmed/27789778
http://dx.doi.org/10.1634/theoncologist.2016-0256

Ejemplares similares